Wake Network, Inc.

A fungi bioscience company focused on advancing psilocybin and medicinal mushroom therapeutics through research and clinical trials. Wake Network has received regulatory approval for what it describes as the world's first double-blind, randomized, placebo-controlled psilocybin microdosing trial using naturally derived whole-mushroom material, conducted with the University of the West Indies in Jamaica.